fenofibrate has been researched along with bilirubin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Fent, K; Popovic, M; Smital, T; Zaja, R | 1 |
| Drouin, P; Morin, C; Panek, E; Siest, G; Steinmetz, J | 1 |
| Fartoux-Heymann, L; Fischer, D; Labayle, D; Narcy-Lambare, B | 1 |
| Iwatsuka, H; Kobayashi, A; Miyakawa, Y; Sugai, S; Takahashi, T; Yamaguchi, T | 1 |
| Beştaş, R; Canoruç, F; Dursun, M; Kidir, V; Yilmaz, S | 1 |
| Akin, O; Alper, M; Cindoruk, M; Erdem, O; Karakan, T; Kerem, M; Salman, B; Unal, S | 1 |
| Arima, T; Higuchi, Y; Koyanagi, M; Maeda, T; Makino, N; Mimori, K; Oyama, J; Sasaki, M | 1 |
| Chan, KH; Donoghoe, MW; Hamer, A; Hoffmann, LS; Keech, AC; Ng, MK; O'Connell, RL; Rajamani, K; Stocker, R; Sullivan, DR; Vanhala, M; Whiting, M; Yu, B | 1 |
| Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Akın, O; Alper, M; Cindoruk, M; Engin, D; Karakan, T; Kerem, M | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
| Cheung, AC; Feld, JJ; Hirschfield, GM; Janssen, HL; Kowgier, M; Lapointe-Shaw, L; Meza-Cardona, J | 1 |
| Dyson, JK; Hegade, VS; Jones, DEJ; Khanna, A; Walker, LJ; Wong, LL | 1 |
| Ardakani, MJE; Gholami, S; Hassani, AH; Hatami, B; Mosala, M; Zali, MR | 1 |
2 trial(s) available for fenofibrate and bilirubin
| Article | Year |
|---|---|
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Alkaline Phosphatase; Bilirubin; Cholangitis, Sclerosing; Female; Fenofibrate; Humans; Liver Function Tests; Male; Middle Aged; Ursodeoxycholic Acid | 2022 |
13 other study(ies) available for fenofibrate and bilirubin
| Article | Year |
|---|---|
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins | 2013 |
Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bilirubin; Child; Child, Preschool; Cholesterol; Fenofibrate; gamma-Glutamyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Propionates; Transaminases; Triglycerides; Uric Acid | 1981 |
[Acute hepatitis and drug dermatitis due to fenofibrate (Secalip)].
Topics: Acute Disease; Adult; Alanine Transaminase; Bilirubin; Biopsy; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Monitoring; Fenofibrate; Fever; gamma-Glutamyltransferase; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Jaundice; Male | 2001 |
Urinary excretion of oxidative metabolites of bilirubin in fenofibrate-treated rats.
Topics: Animals; Bilirubin; Catalase; Dose-Response Relationship, Drug; Fenofibrate; Hypolipidemic Agents; Liver; Organ Size; Oxidation-Reduction; Peroxisomes; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Stress, Physiological | 2003 |
Fenofibrate treatment in two adults with Crigler-Najjar syndrome type II.
Topics: Adolescent; Adult; Bilirubin; Crigler-Najjar Syndrome; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male | 2006 |
Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study.
Topics: Animals; Apoptosis; Bile Ducts; Bilirubin; Cholestasis; Cytokines; Fenofibrate; Hepatocytes; Inflammation Mediators; Jaundice, Obstructive; Ligation; Liver; Male; Malondialdehyde; PPAR alpha; Rats; Rats, Wistar | 2007 |
The correlation between clinical laboratory data and telomeric status of male patients with metabolic disorders and no clinical history of vascular events.
Topics: Aged; Aged, 80 and over; Aging; Bilirubin; Clinical Laboratory Techniques; Creatine Kinase; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hyperlipidemias; Hypoglycemic Agents; Japan; Leukocytes; Male; Middle Aged; Outpatients; Polymorphism, Restriction Fragment Length; Sulfonylurea Compounds; Telomere | 2011 |
Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Aged; Amputation, Surgical; Antioxidants; Bilirubin; Biomarkers; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Lower Extremity; Male; Middle Aged; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Treatment Outcome | 2013 |
Diabetes, bilirubin and amputations: is there a link?
Topics: Amputation, Surgical; Bilirubin; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Lower Extremity; Male | 2013 |
PPAR-alpha agonist treatment increases trefoil factor family-3 expression and attenuates apoptosis in the liver tissue of bile duct-ligated rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Apoptosis; Aspartate Aminotransferases; Bile Ducts; Bilirubin; Fenofibrate; gamma-Glutamyltransferase; Hypolipidemic Agents; Interleukin-1beta; Ligation; Lipid Peroxidation; Liver; Male; Malondialdehyde; Neuropeptides; PPAR alpha; Rats; Rats, Wistar; RNA, Messenger; Trefoil Factor-3; Tumor Necrosis Factor-alpha | 2013 |
Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
Topics: Adult; Aged; Alkaline Phosphatase; Bilirubin; Cholagogues and Choleretics; Cohort Studies; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ursodeoxycholic Acid | 2016 |
Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Topics: Alanine Transaminase; Alkaline Phosphatase; Bilirubin; Cholagogues and Choleretics; Cohort Studies; Creatinine; Drug Therapy, Combination; Female; Fenofibrate; Glomerular Filtration Rate; Humans; Hypolipidemic Agents; Liver Cirrhosis, Biliary; Longitudinal Studies; Middle Aged; Prognosis; Retrospective Studies; Serum Albumin; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2016 |